Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02583399 · ClinicalTrials.gov registry record · Phase 4
Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients
A Phase 4 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT02583399 is a Phase 4 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT02583399, a Phase 4 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the pharmacokinetic profile of a single dose of intravenous ibuprofen administered over approximately ten (10) minutes.
Interventions
- DRUG Ibuprofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-08-08 |
| Est. Completion | 2019-07-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02583399
The ClinicalTrials.gov registry entry for NCT02583399 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibuprofen is the first listed.
NCT02583399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02583399 about?
NCT02583399 is a clinical study titled "Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients". The primary objective of this study is to evaluate the pharmacokinetic profile of a single dose of intravenous ibuprofen administered over approximately ten (10) minutes.
What is the current status of trial NCT02583399?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2017-08-08. Estimated completion is 2019-07-02.
What interventions are being tested in trial NCT02583399?
The interventions under investigation include: Ibuprofen (DRUG).
Who is sponsoring clinical trial NCT02583399?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.